Vol.

No.

April 12, 2024Apr 12, 2024

DOWNLOAD THE PDF

Pooled analysis questions reliability of an endpoint used in multi-cancer detection trials

Cover Story

Clinical

Pooled analysis questions reliability of an endpoint used in multi-cancer detection trials

An analysis by researchers from the International Agency for Research on Cancer casts doubt on validity of an endpoint used in key studies of multi-cancer detection tests.

NCI Director's Report

Rathmell: To improve funding outlook, we must reverse distrust in science

By Matthew Bin Han Ong

Health Equity

NCI creates Cancer Equity Leaders group to improve cancer health equity

By Matthew Bin Han Ong

Guest Editorial

Association of Cancer Center Administrators holds inaugural meeting in Philadelphia

By Lauren Langbein

Free Obituary

Edward Copeland, surgeon and breast cancer expert, dies at 86

By Bulletin editorial team, American College of Surgeons

Free In the Archives

Edward M. Copeland III: “My lifestyle was practicing surgery”

My bad: I left out Fox Chase

By Paul Goldberg

In Brief

Julie Bauman, Stephanie Blank to lead NRG Oncology Cancer Prevention & Control Committee

Matt Kalaycio named chair of board of directors at NCCN

Nancy Hanley Eriksson, Kevin Conroy receive TGen’s John S. McCain Leadership Awards

OSU—James Immunotherapy Management Clinic to focus on managing immune side effects and cancer control

NYU Dentistry’s Pain Research Center receives $8M NIH grant to study oral cancer pain

UAMS to receive $1M from Judd Hill Foundation

Funding Opportunities

DOD Lung Cancer Research Program funding opportunities for FY24

Clinical Roundup

Radiation before mastectomy cuts time delays for reconstructive surgery in breast cancer patients

Imfinzi improves OS and PFS in limited-stage LS-SCLC in phase III trial

Phase I/II trial of linvoseltamab in R/R MM produces positive pivotal data

Non-classical mutations present in 20-30% of all patients with EGFR-mutated NSCLC, analysis shows

Drugs & Targets

FDA grants accelerated approval to Enhertu for unresectable or metastatic HER2-positive solid tumors

EC expands approval of Reblozyl to first-line treatment of anemia in MDS

PREVIOUS ISSUE

NEXT ISSUE

Recent Issues